|

Ticagrelor Clinical Trials

6 actively recruiting trials

Also known as: Brilinta/Brilique, Brilique

Pipeline

Phase 3: 1Phase 4: 4

Top Sponsors

Shanghai Zhongshan Hospital1
Shanghai Tong Ren Hospital1
Radboud University Medical Center1
Medical University of Gdansk1
Fu Wai Hospital, Beijing, China1

Indications

Heart Disease5
Acute Coronary Syndrome2
Coronary Artery Disease2
Antiplatelet Drugs1
Interventional Cardiology1

Other6 trials

A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients

Phase 4

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Phase 4

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Phase 4

SAPT Versus DAPT in Incomplete Revascularization After CABG

Phase 3

Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage

N/A

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.